Massie Technology Group, Inc.

Ophthalmic AI Driven Retinal Scanning Technology - Patent Pending - Ready for Market

Massie Technology Group, Inc, “MTG”

San Ramon, California USA

Massie Technology Group Introduces APEX — A Breakthrough AI + Advanced Optics Retinal Imaging Platform

Massie Technology Group, Inc. (MTG) has launched the APEX, a patented Retinal Imaging Platform that fuses precision optics with AI‑driven diagnostic intelligence. APEX is engineered to redefine early detection of vision disorders and unlock new diagnostic visibility into neurological, metabolic, and oncologic diseases detectable through high‑resolution retinal imaging — a rapidly expanding field known as Oculomics.

For more than two decades, retinal imaging has been constrained by outdated, inequitable technologies that routinely fail to capture accurate images in patients with darkly pigmented retinas. APEX eliminates these barriers. Its advanced optics and AI algorithms deliver accurate, inclusive, and accessible imaging across all retinal pigment types, enabling clinicians to diagnose earlier, intervene sooner, and prevent irreversible systemic damage.

APEX is designed for all stages of life, with particular impact in pediatric ophthalmology where early intervention determines lifelong outcomes. Its portability and telemedicine‑ready architecture allow non‑specialists to perform scans anywhere, transmitting AI‑enhanced imaging data to ophthalmologists for rapid evaluation and treatment guidance.

Experienced Leadership & Strategic Positioning
MTG is led by senior executives with deep expertise in optics engineering, regulatory strategy, clinical operations, and commercialization. Members MTG’s management team were instrumental in the engineering, development and marketing of two leading (obsolescent) retinal imaging systems currently on the market. MTG is supported by top‑tier ophthalmic Key Opinion Leaders (KOLs) who are actively shaping expanded diagnostic applications and preparing for early adoption.

Clinical Demand & Market Validation
APEX will launch with a focus on early pediatric disease detection, including underserved communities where portable imaging and telemedicine access are essential. Adult diagnostic applications — including OCT — will follow.

MTG has generated strong interest from respected ophthalmic KOLs. Many KOL's have expressed intent to purchase APEX units and are collaborating with MTG to broaden diagnostic applications. With clinical validation completed through founder investment, MTG anticipates commercial availability within one year.

About Massie Technology Group, Inc.
Massie Technology Group develops advanced diagnostic imaging technologies that merge precision optics with AI to improve early disease detection and expand access to high‑quality vision and neurological care. MTG is headquartered in San Ramon, California.

For Additional Information

Nathan F. Messinger
Chief Operating Officer
Massie Technology Group, Inc.
(912.656.2696) (EST) (N.Y. Time)
[email protected]

Fundraise Details

This section is only visible to registered investors. Log in or register as an accredited investor to view.

Ready to Ask For Funding for your company?

Post a Funding Request

Massie Technology Group, Inc.

Fundraise Details

Key Facts